Skip to main content
Premium Trial:

Request an Annual Quote

Ion Torrent Sponsors Carnegie Mellon Project to Develop Clinical Genome Interpretation Software

Premium

Life Technologies' Ion Torrent is sponsoring a project at Carnegie Mellon University to develop open-source software that will help clinicians interpret human genomes, the institutions said this week.

Robert Murphy, director of the Lane Center for Computational Biology in Carnegie Mellon's School of Computer Science, will lead the multidisciplinary CMU team. Scientists at Baylor College of Medicine and at Yale University will provide whole-genome sequencing and patient data for the project.

Also involved will be Jaime Carbonell, director of CMU's language technologies institute, and Tom Mitchell, director of CMU's machine learning department.

Ion Torrent is funding the project during its first year with an undisclosed amount, and additional funding is expected to come from federal grants and other sources.

The ultimate goal is to develop a "doctor in a box" software that would diagnose disease, identify disease susceptibility, and predict drug response based on a person's genome sequence. Murphy said that new machine-learning tools will aid in the development of the software, which will be trained to analyze sequence data produced by Ion Torrent.

"It's an enormous undertaking," said Murphy in a statement, "but we are creating a framework that will allow us to tackle this problem one piece at a time and to do so at a scale that makes sense when all of those pieces are put together."

In the first year, the team plans to identify genomic features associated with a yet-to-be-determined disease or a patient population.

Scientists led by Richard Gibbs at Baylor's Human Genome Sequencing Center and Shrikant Mane at Yale's Center for Genome Analysis will perform whole-genome sequencing of patients and provide longitudinal medical records for them. These records will include treatments and outcomes as well as clinical test results.

Carnegie Mellon researchers will use machine-learning programs to analyze the anonymized data to find relationships between genomic data and clinical outcomes, and will incorporate information on genes and proteins from the literature. The result will be models that can be used to predict disease susceptibility and treatment response.

To support the project, Ion Torrent CEO Jonathan Rothberg will sponsor a scientific conference at Carnegie Mellon this summer or fall, called "Analyzing the $1,000 Genome."

Carnegie Mellon is joining a number of other projects and companies developing human genome interpretation software, including Knome, Omicia, GenomeQuest, Personalis, Cypher Genomics, the University of Utah, the Medical College of Wisconsin, and Harvard Medical School's Partners HealthCare Center for Personalized Genetic Medicine.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.